NEW YORK (AP) -- Irish drugmaker Mallinckrodt said Monday it will buy privately held immunotherapy company Therakos for $1.33 billion. Therakos' Photopheresis system collects immune cells from a patient's blood, treats the cells with ultraviolet light to activate them, and returns them to the patient's body so they can attack a disease. In the U.S. its system is used to treat skin problems caused by cutaneous T-cell lymphoma, a type of blood cancer that involves the skin. It's approved for... More